Liraglutide.

Liraglutide is an approved drug in the glp-1 & incretin receptor agonists.

Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.

It draws interest for glp-1 & incretin receptor agonists and is prescribed for its approved indication(s).

Yes for its approved use(s), with caveats — strong human trial evidence underpins the label, but broader wellness/longevity claims are not proven.

What it is

Liraglutide is a long-acting, injectable glucagon-like peptide-1 (GLP-1) receptor agonist — an acylated analog of the human incretin hormone GLP-1. It is roughly 97% homologous to native GLP-1, differing by an arginine-for-lysine substitution at position 34 and a C16 palmitic-acid chain attached via a glutamic-acid spacer at lysine 26. That fatty-acid acylation promotes reversible binding to serum albumin and self-association, slowing degradation and renal clearance enough to extend its action to once-daily dosing. It is marketed by Novo Nordisk as Victoza (type 2 diabetes) and Saxenda (chronic weight management), and is now also available as an FDA-approved generic.

How it works

Liraglutide binds and activates the GLP-1 receptor, a Gs-protein-coupled receptor that raises intracellular cyclic AMP. In pancreatic beta cells this potentiates glucose-dependent insulin secretion, meaning insulin release is amplified mainly when blood glucose is elevated; it also suppresses inappropriately high glucagon secretion from alpha cells, which together improve postprandial and fasting glucose. Because the effect is glucose-dependent, GLP-1 agonism carries low intrinsic hypoglycemia risk as monotherapy. Liraglutide additionally slows gastric emptying and acts on hypothalamic appetite circuits to increase satiety and reduce food intake, the basis for its weight-lowering effect.

What the evidence shows

Human evidence for liraglutide is extensive and high-quality, not preclinical extrapolation. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; n=9,340 with type 2 diabetes at high cardiovascular risk, median 3.8-year follow-up) found a lower rate of the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke versus placebo, plus lower cardiovascular and all-cause mortality; its design was prespecified (Marso et al., Am Heart J 2013). For obesity, the 56-week SCALE trial in adults without diabetes (Pi-Sunyer et al., NEJM 2015; n=3,731) showed significantly greater weight loss with liraglutide 3.0 mg plus lifestyle than with placebo plus lifestyle. Liraglutide has also been studied in adolescents with obesity and in prediabetes. The main human gaps now are comparative: newer agents such as semaglutide and tirzepatide produce larger weight reductions in head-to-head and cross-trial comparisons, and liraglutide's once-daily injection is a practical disadvantage.

Safety considerations

The most common documented adverse effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually dose-related and most pronounced early in treatment. Labeled warnings include acute pancreatitis, acute gallbladder disease (cholelithiasis/cholecystitis), acute kidney injury (often in the setting of dehydration from GI losses), and increased heart rate; in glucose-lowering combinations with insulin or sulfonylureas, hypoglycemia risk rises. Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent medullary thyroid carcinoma findings, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2; whether this risk translates to humans remains unresolved. Long-term safety in non-medical, non-prescribed "research" use is uncharacterized, and unregulated/compounded sources add contamination and mislabeling risks.

Regulatory status

FDA-approved: as Victoza (2010) for type 2 diabetes in adults and later adolescents, and as Saxenda (2014) for chronic weight management; a generic liraglutide injection has since been approved. It is a legitimately prescribed medication, not a research-only compound, and is not a banned substance under standard anti-doping frameworks the way some hormones are.

1. [1]Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) — New England Journal of Medicine, 2016, PMID 27295427
2. [2]A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE) — New England Journal of Medicine, 2015, PMID 26132939
3. [3]Design of the LEADER trial (liraglutide effect and action in diabetes: cardiovascular outcome results) — American Heart Journal, 2013, PMID 24176437
4. [4]VICTOZA (liraglutide) injection — FDA prescribing information — FDA/accessdata label, 2023

• Strong evidence for approved uses; common effects are gastrointestinal.
• See the FDA label for warnings and contraindications.

Stack fit

Why not A: supported by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Liraglutide is an FDA-approved drug for specific indications.
• It belongs to the GLP-1 & incretin receptor agonists class.
• Its principal mechanism is characterized in the literature.

• Long-term safety in healthy users, and full drug-interaction risk.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.

1. What it is
2. The GLP-1 receptor agonism mechanism
3. The approval lane
4. Why Established, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently